Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PsychoGenics has entered into a drug discovery agreement with Cephalon. Under the terms of the deal, Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.
Subscribe to our email newsletter
PsychoGenics and Cephalon expect to jointly identify drug candidates suitable for clinical development. If Cephalon develops clinical candidates, PsychoGenics will receive milestone payments as well as royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.
Dr Emer Leahy, president and CEO of PsychoGenics, said: “We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”